170487-01-1

Upstream product

• 1121-60-4 pyridine-2-carbaldehyde 
• 62456-33-1 2-(2-bromo-3-((tetrahydropyran-2-yloxy)methyl)benzyloxy)tetrahydropyran 
• 167166-38-3 1-(2-pyridyl)-1-<2,6-bis<(tetrahydro-2H-2-pyranyloxy)methyl>phenyl>methanol 

Relevant academic research and scientific papers

Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof

Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment of neurodegenerative disorders or neurotoxic injuries utilizing them, wherein the substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts have the formula: STR1 wherein: R1, R2, R3, R4, R5, R6, R7, X and p are as defined in the specification.

Novel benzo[b]quinolizinium cations as uncompetitive N-methyl-D-aspartic acid (NMDA) antagonists: The relationship between log D and agonist independent (closed) NMDA channel block

A series of permanently charged benzo[b]quinolizinium cations having lower lipophilicity than MK-801 or phencyclidine (PCP) were synthesized. Data relating agonist independent block of N-methyl-D-aspartic acid (NMDA) ion channels to log D are described. C